National Institutes of Health: Telangiectasis trials

The registry lists 10 Telangiectasis studies with National Institutes of Health as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 1Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel GrowthCompletedNCT00685854Phase 1
• Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel GrowthCompletedNCT00685503Phase 1
• Screening Behavior in Adults With Hereditary Hemorrhagic TelangiectasiaCompletedNCT00684879
• Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel FormationCompletedNCT00457145Phase 1
• Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel FormationCompletedNCT00457067Phase 1
• Epidemiology of Venous DiseaseCompletedNCT00005392
• Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic TelangiectasiaCompletedNCT00004654Phase 3
• Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia PatientsCompletedNCT00004649
• Studies of Hereditary Hemorrhagic TelangiectasiaCompletedNCT00004648
• Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile EctasiaCompletedNCT00004327Phase 2